Vivimed Labs Admitted to Corporate Insolvency Resolution Process (CIRP)
Vivimed Labs Limited has been admitted to the Corporate Insolvency Resolution Process (CIRP) by the NCLT, Bengaluru, on April 15, 2026. The admission is due to an unpaid operational debt of ₹32.78 crore owed to Blue Cube Germany Assets GmbH & Co.KG. An Interim Resolution Professional has been appointed, and a moratorium has been declared.
Admission to CIRP signifies a critical financial situation, leading to a moratorium on its assets, appointment of an IRP, and a complete overhaul of its management and operations. This has a significant and immediate impact on the company's stakeholders, including shareholders, creditors, and employees.
The company has been admitted to the Corporate Insolvency Resolution Process (CIRP), which is a severe negative event indicating financial distress and potential loss of control for the company's management and shareholders.
Vivimed Labs Limited has been admitted to the Corporate Insolvency Resolution Process (CIRP) by the National Company Law Tribunal (NCLT), Bengaluru Bench, following an order dated April 15, 2026. The admission follows a petition filed by Blue Cube Germany Assets GmbH & Co.KG, an operational creditor, for a debt amounting to ₹32,78,60,844 (including interest).
The NCLT order, uploaded on April 17, 2026, marks the initiation of CIRP against Vivimed Labs. The tribunal noted that the debt arose from the supply of 'perchloroethylene' and that the company had failed to honour its commitments, including an undertaking to pay in instalments. Vivimed Labs had acknowledged its liability in previous communications and court filings, including memos dated November 10, 2021, and December 7, 2021.
The tribunal rejected Vivimed Labs' objections regarding the maintainability of the petition, pendency of execution proceedings, and limitation. It established that the debt was an operational debt and that acknowledgments of liability and the exclusion of the COVID-19 pandemic period kept the petition within the limitation period. The NCLT also appointed Shri T NARAYANA SWAMY as the Interim Resolution Professional (IRP) and declared a moratorium under Section 14 of the Insolvency and Bankruptcy Code, 2016, prohibiting the institution or continuation of suits, transfer of assets, and recovery of secured interests.
The case is listed for further hearing on June 24, 2026, awaiting the IRP's report. The operational creditor is required to deposit ₹2,00,000 with the IRP for initial expenses.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under corporate insolvency resolution process. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.